Biosimilar Financing is a pharmaceutical financing mechanism that specifically governs the economic strategies, reimbursement models, and investment structures supporting the development, production, and market accessibility of biosimilar drugs, distinguishing it from financing models for originator biologics or small-molecule generics.
40
Publications
1.8K
Citations
189
Authors
118
Institutions
Publications per year
2017–2026
27
Parents
Publications
40
Shift From Adalimumab Originator to Biosimilars in Denmark
Thomas Bo Jensen, Seoyoung C. Kim, Espen Jimenez‐Solem et al. · JAMA Internal Medicine · 2020 · 89 citations · Full text
1–5 of 40
Authors
189
- AG
3
h-index
- EM
3
h-index
- BG
3
h-index
- SS
3
h-index
- AS
2
h-index
1–5 of 189
Institutions
118
KU Leuven
Leuven, Belgium
5 h-index
12 publications
844 citations
University of Strathclyde
Glasgow, United Kingdom
3 h-index
4 publications
160 citations
Brigham and Women's Hospital
Boston, United States
3 h-index
11 publications
307 citations
Erasmus MC
Rotterdam, The Netherlands
3 h-index
4 publications
285 citations
Karolinska University Hospital
Stockholm, Sweden
2 h-index
2 publications
79 citations
George Washington University
Washington, United States
2 h-index
2 publications
93 citations
Karolinska Institutet
Stockholm, Sweden
2 h-index
2 publications
79 citations
University of Pittsburgh
Pittsburgh, United States
2 h-index
3 publications
49 citations
1–8 of 118
Venues
- Generics and Biosimilars Initiative Journal
4 publications · 91 citations
4
h-index
- JAMA Internal Medicine
3 publications · 149 citations
3
h-index
- PubMed
Repository · 2 publications · 71 citations
2
h-index
- New England Journal of Medicine
NEJM · 2 publications · 115 citations
2
h-index
- American Journal of Health-System Pharmacy
AJHP · 2 publications · 26 citations
2
h-index
1–5